Condition: Friedreich Ataxia · Cardiomyopathy, Secondary · Sponsor: Lexeo Therapeutics
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
This description comes directly from the study's public registry record.
Lexeo Clinical Trials · 212-547-9879 · clinicaltrials@lexeotx.com
Always discuss trial participation with your own doctor first.
| University of South Florida | Tampa, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07721025